Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers
Ricardo Spielberger, M.D., Patrick Stiff, M.D., William Bensinger, M.D., Teresa Gentile, M.D., Ph.D., Daniel Weisdorf, M.D., Tarun Kewalramani, M.D., Thomas Shea, M.D., Saul Yanovich, M.D., Keith Hansen, M.D., Stephen Noga, M.D., Ph.D., John McCarty, M.D., C. Frederick LeMaistre, M.D., Eric C. Sung, D.D.S., Bruce R. Blazar, M.D., Dieter Elhardt, Ph.D., Mon-Gy Chen, M.S., and Christos Emmanouilides, M.D.
Background Oral mucositis is a complication of intensive chemotherapyand radiotherapy with no effective treatment. We tested theability of palifermin (recombinant human keratinocyte growthfactor) to decrease oral mucosal injury induced by cytotoxictherapy.
Methods This double-blind study compared the effect of paliferminwith that of a placebo on the development of oral mucositisin 212 patients with hematologic cancers; 106 patients receivedpalifermin (60 µg per kilogram of body weight per day)and 106 received a placebo intravenously for three consecutivedays immediately before the initiation of conditioning therapy(fractionated total-body irradiation plus high-dose chemotherapy)and after autologous hematopoietic stem-cell transplantation.Oral mucositis was evaluated daily for 28 days after transplantation.
Results The incidence of oral mucositis of World Health Organization(WHO) grade 3 or 4 was 63 percent in the palifermin group and98 percent in the placebo group (P<0.001). Among patientswith this degree of mucositis, the median duration of mucositiswas 6 days (range, 1 to 22) in the palifermin group and 9 days(range, 1 to 27) in the placebo group. Among all patients, regardlessof the occurrence of mucositis, the median duration of oralmucositis of WHO grade 3 or 4 was 3 days (range, 0 to 22) inthe palifermin group and 9 days (range, 0 to 27) in the placebogroup (P<0.001). As compared with placebo, palifermin wasassociated with significant reductions in the incidence of grade4 oral mucositis (20 percent vs. 62 percent, P<0.001), patient-reportedsoreness of the mouth and throat (area-under-the-curve score,29.0 [range, 0 to 98] vs. 46.8 [range, 0 to 110]; P<0.001),the use of opioid analgesics (median, 212 mg of morphine equivalents[range, 0 to 9418] vs. 535 mg of morphine equivalents [range,0 to 9418], P<0.001), and the incidence of use of total parenteralnutrition (31 percent vs. 55 percent, P<0.001). Adverse events,mainly rash, pruritus, erythema, mouth and tongue disorders,and taste alteration, were mild to moderate in severity andwere transient.
Conclusions Palifermin reduced the duration and severity oforal mucositis after intensive chemotherapy and radiotherapyfor hematologic cancers.
Source Information
From the City of Hope National Medical Center, Duarte, Calif. (R.S.); Loyola University Medical Center, Maywood, Ill. (P.S.); the Fred Hutchinson Cancer Research Center, Seattle (W.B.); State University of New York Upstate Medical University, Syracuse (T.G.); the University of Minnesota, Minneapolis (D.W., B.R.B.); Memorial Sloan-Kettering Cancer Center, New York (T.K.); the University of North Carolina, Chapel Hill (T.S.); Georgetown University Cancer Center, Washington, D.C. (S.Y.); the Northwest Marrow Transplant Center, Portland, Oreg. (K.H.); Sinai Hospital of Baltimore, Baltimore (S.N.); the Medical College of Virginia, Richmond (J.M.); the Texas Transplant Institute, San Antonio (C.F.L.); the School of Dentistry (E.C.S.) and the Division of Hematology/Oncology (C.E.), University of California at Los Angeles, Los Angeles; and Amgen, Thousand Oaks, Calif. (D.E., M.-G.C.).
Address reprint requests to Dr. Spielberger at the City of Hope National Medical Center, Department of Hematology and Hematopoietic Cell Transplantation and Kaiser Permanente BMT Program, 1500 E. Duarte Rd., Duarte, CA 91010, or at rspielberger{at}coh.org.
Palifermin and Chemotherapy-Induced Oral Mucositis
Awada A., Genot M.-T., Klastersky J., Köstler W. J., Hejna M., Zielinski C. C., Palmieri C., Vigushin D., Spielberger R., Stiff P., Bensinger W.
Extract |
Full Text |
PDF
N Engl J Med 2005;
352:1264-1265, Mar 24, 2005.
Correspondence
This article has been cited by other articles:
Lazarus, H. M., Phillips, G. L., Herzig, R. H., Hurd, D. D., Wolff, S. N., Herzig, G. P.
(2008). High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later. JCO
26: 2240-2243
[Full Text]
Schmidt, E., Thoennissen, N. H., Rudat, A., Bieker, R., Schliemann, C., Mesters, R. M., Zuhlsdorf, M., Muller-Tidow, C., Berdel, W. E.
(2008). Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. Ann Oncol
0: mdn179v1-mdn179
[Abstract][Full Text]
Thompson, J. A., Fisher, R. I., LeBlanc, M., Forman, S. J., Press, O. W., Unger, J. M., Nademanee, A. P., Stiff, P. J., Petersdorf, S. H., Fefer, A.
(2008). Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood
111: 4048-4054
[Abstract][Full Text]
Vuyyuri, S. B., Hamstra, D. A., Khanna, D., Hamilton, C. A., Markwart, S. M., Campbell, K. C.M., Sunkara, P., Ross, B. D., Rehemtulla, A.
(2008). Evaluation of D-Methionine as a Novel Oral Radiation Protector for Prevention of Mucositis. Clin. Cancer Res.
14: 2161-2170
[Abstract][Full Text]
Blijlevens, N., Schwenkglenks, M., Bacon, P., D'Addio, A., Einsele, H., Maertens, J., Niederwieser, D., Rabitsch, W., Roosaar, A., Ruutu, T., Schouten, H., Stone, R., Vokurka, S., Quinn, B., McCann, S.
(2008). Prospective Oral Mucositis Audit: Oral Mucositis in Patients Receiving High-Dose Melphalan or BEAM Conditioning Chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. JCO
26: 1519-1525
[Abstract][Full Text]
Brizel, D. M.
(2007). Pharmacologic Approaches to Radiation Protection. JCO
25: 4084-4089
[Abstract][Full Text]
Seggewiss, R., Lore, K., Guenaga, F. J., Pittaluga, S., Mattapallil, J., Chow, C. K., Koup, R. A., Camphausen, K., Nason, M. C., Meier-Schellersheim, M., Donahue, R. E., Blazar, B. R., Dunbar, C. E., Douek, D. C.
(2007). Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques.. Blood
110: 441-449
[Abstract][Full Text]
Hom, D. B., Linzie, B. M., Huang, T. C.
(2007). The Healing Effects of Autologous Platelet Gel on Acute Human Skin Wounds. Arch Facial Plast Surg
9: 174-183
[Abstract][Full Text]
Blijlevens, N, Sonis, S
(2007). Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol
18: 817-826
[Abstract][Full Text]
Min, D., Panoskaltsis-Mortari, A., Kuro-o, M., Hollander, G. A., Blazar, B. R., Weinberg, K. I.
(2007). Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. Blood
109: 2529-2537
[Abstract][Full Text]
Niscola, P., Romani, C., Cupelli, L., Scaramucci, L., Tendas, A., Dentamaro, T., Amadori, S., de Fabritiis, P.
(2007). Mucositis in patients with hematologic malignancies: an overview. haematol
92: 222-231
[Abstract][Full Text]
Reiter, A.
(2007). Diagnosis and Treatment of Childhood Non-Hodgkin Lymphoma. ASH Education Book
2007: 285-296
[Abstract][Full Text]
McDonnell, A. M, Lenz, K. L
(2007). Palifermin: Role in the Prevention of Chemotherapy- and Radiation-Induced Mucositis. The Annals of Pharmacotherapy
41: 86-94
[Abstract][Full Text]
Braun, S., Krampert, M., Bodo, E., Kumin, A., Born-Berclaz, C., Paus, R., Werner, S.
(2006). Keratinocyte growth factor protects epidermis and hair follicles from cell death induced by UV irradiation, chemotherapeutic or cytotoxic agents. J. Cell Sci.
119: 4841-4849
[Abstract][Full Text]
Gillespie, B., Zia-Amirhosseini, P., Salfi, M., Kakkar, T., Wang, J., Gupta, S., Smith, B., Robson, R., Sullivan, J. T.
(2006). Effect of renal function on the pharmacokinetics of palifermin.. J Clin Pharmacol
46: 1460-1468
[Abstract][Full Text]
Stiff, P. J., Emmanouilides, C., Bensinger, W. I., Gentile, T., Blazar, B., Shea, T. C., Lu, J., Isitt, J., Cesano, A., Spielberger, R.
(2006). Palifermin Reduces Patient-Reported Mouth and Throat Soreness and Improves Patient Functioning in the Hematopoietic Stem-Cell Transplantation Setting. JCO
24: 5186-5193
[Abstract][Full Text]
Rosen, L. S., Abdi, E., Davis, I. D., Gutheil, J., Schnell, F. M., Zalcberg, J., Cesano, A., Gayko, U., Chen, M.-G., Clarke, S.
(2006). Palifermin Reduces the Incidence of Oral Mucositis in Patients With Metastatic Colorectal Cancer Treated With Fluorouracil-Based Chemotherapy. JCO
24: 5194-5200
[Abstract][Full Text]
Loprinzi, C. L., Barton, D. L., Sloan, J. A.
(2006). Whose Opinion Counts?. JCO
24: 5183-5185
[Full Text]
Blazar, B. R., Weisdorf, D. J., DeFor, T., Goldman, A., Braun, T., Silver, S., Ferrara, J. L. M.
(2006). Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood
108: 3216-3222
[Abstract][Full Text]
Stokman, M.A., Spijkervet, F.K.L., Boezen, H.M., Schouten, J.P., Roodenburg, J.L.N., de Vries, E.G.E.
(2006). Preventive Intervention Possibilities in Radiotherapy- and Chemotherapy-induced Oral Mucositis: Results of Meta-analyses.. J. Dent. Res.
85: 690-700
[Abstract][Full Text]
Finch, P. W., Rubin, J. S.
(2006). Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors.. JNCI J Natl Cancer Inst
98: 812-824
[Abstract][Full Text]
de Koning, B. A., van Dieren, J. M, Lindenbergh-Kortleve, D. J, van der Sluis, M., Matsumoto, T., Yamaguchi, K., Einerhand, A. W, Samsom, J. N, Pieters, R., Nieuwenhuis, E. E.
(2006). Contributions of mucosal immune cells to methotrexate-induced mucositis. Int Immunol
18: 941-949
[Abstract][Full Text]
Berger, M. E., Christensen, D. M., Lowry, P. C., Jones, O. W., Wiley, A. L.
(2006). Medical management of radiation injuries: current approaches. Occup Med (Lond)
56: 162-172
[Abstract][Full Text]
Copelan, E. A.
(2006). Hematopoietic stem-cell transplantation.. NEJM
354: 1813-1826
[Full Text]
Glass, B., Kloess, M., Bentz, M., Schlimok, G., Berdel, W. E., Feller, A., Trumper, L., Loeffler, M., Pfreundschuh, M., Schmitz, N., for the German High-Grade Non-Hodgkin Lymphoma Stu,
(2006). Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood
107: 3058-3064
[Abstract][Full Text]
Alpdogan, O., Hubbard, V. M., Smith, O. M., Patel, N., Lu, S., Goldberg, G. L., Gray, D. H., Feinman, J., Kochman, A. A., Eng, J. M., Suh, D., Muriglan, S. J., Boyd, R. L., van den Brink, M. R. M.
(2006). Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration. Blood
107: 2453-2460
[Abstract][Full Text]
Rosenthal, D. I.
(2006). Established and emerging uses of cytoprotection in head and neck cancer.. Arch Otolaryngol Head Neck Surg
132: 129-130
[Full Text]
Chang, Y., Wang, J., Lu, X., Thewke, D. P., Mason, R. J.
(2005). KGF induces lipogenic genes through a PI3K and JNK/SREBP-1 pathway in H292 cells. J. Lipid Res.
46: 2624-2635
[Abstract][Full Text]
Stelljes, M., Bornhauser, M., Kroger, M., Beyer, J., Sauerland, M. C., Heinecke, A., Berning, B., Scheffold, C., Silling, G., Buchner, T., Neubauer, A., Fauser, A. A., Ehninger, G., Berdel, W. E., Kienast, J., for the Cooperative German Transplant Study Group,
(2005). Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood
106: 3314-3321
[Abstract][Full Text]
Radtke, M. L, Kolesar, J. M
(2005). Palifermin (KepivanceTM) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support. J Oncol Pharm Pract
11: 121-125
[Abstract]
Redding, S. W.
(2005). Cancer Therapy-Related Oral Mucositis. J Dent Educ
69: 919-929
[Abstract][Full Text]
Ladas, E. J., Sacks, N., Meacham, L., Henry, D., Enriquez, L., Lowry, G., Hawkes, R., Dadd, G., Rogers, P.
(2005). A Multidisciplinary Review of Nutrition Considerations in the Pediatric Oncology Population: A Perspective From Children's Oncology Group. Nutr Clin Pract
20: 377-393
[Abstract][Full Text]
Lipkin, A. C., Lenssen, P., Dickson, B. J.
(2005). Nutrition Issues in Hematopoietic Stem Cell Transplantation: State of the Art. Nutr Clin Pract
20: 423-439
[Abstract][Full Text]
Ladas, E. J., Sacks, N., Meacham, L., Henry, D., Enriquez, L., Lowry, G., Hawkes, R., Dadd, G., Rogers, P.
(2005). A Multidisciplinary Review of Nutrition Considerations in the Pediatric Oncology Population: A Perspective From Children's Oncology Group. (SAGE) Nutr Clin Pract
20: 377-393
[Abstract][Full Text]
Lipkin, A. C., Lenssen, P., Dickson, B. J.
(2005). Nutrition Issues in Hematopoietic Stem Cell Transplantation: State of the Art. (SAGE) Nutr Clin Pract
20: 423-439
[Abstract][Full Text]
Kober, T., Bohlius, J., Trelle, S., Engert, A.
(2005). Second Biannual Report of the Cochrane Haematological Malignancies Group. JNCI J Natl Cancer Inst
97: E1-E
[Full Text]
Awada, A., Genot, M.-T., Klastersky, J., Kostler, W. J., Hejna, M., Zielinski, C. C., Palmieri, C., Vigushin, D., Spielberger, R., Stiff, P., Bensinger, W.
(2005). Palifermin and Chemotherapy-Induced Oral Mucositis. NEJM
352: 1264-1265
[Full Text]
Garfunkel, A. A.
(2004). Oral Mucositis -- The Search for a Solution. NEJM
351: 2649-2651
[Full Text]
Previous
